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background:  There are limited data comparing the safety and efficacy of newer generation Platinum Chromium Everolimus-eluting Stent 
(PtCr-EES, Promus ElementTM, Boston Scientific) with Cobalt Chromium EES (CoCr-EES, PromusTM, Boston Scientific and XienceTM, 
Abbott Vascular) in a series of Asian population.
methods:  A total of 676 patients (pts) receiving PtCr-EES or CoCr-EES were pooled from our prospective percutaneous coronary 
intervention (PCI) registry from June 2008 to May 2012. To adjust potential confounders, a propensity score matched (PSM) analysis was 
performed using the logistic regression model. Mid-term angiographic outcomes and clinical outcomes were compared between the two 
groups up to 2 years.
results:  After PSM analysis, 2 propensity-matched groups (218 pairs, n = 436 pts, C-statistic=0.721) were generated and the baseline 
characteristics of the two groups were balanced. At six to 9-month angiographic and Two-year clinical outcomes, there were similar 
incidence of binary in-stent restenosis and hard endpoints including mortality, myocardial infarction, target lesion revascularization (TLR), 
target vessel revascularization (TVR), non-target vessel revascularization (NTVR) and major adverse cardiac events (MACEs,Table).
Conclusion:  Despite the expected beneficial effects by the enhanced visualization and improved mechanical property, PtCr-EES were 
showed similar mid-term angiographic and 2-year clinical outcomes compared with CoCr-EES.
 
